Records containing: Relapsing Remitting Multiple Sclerosis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2021-08-18Teriflunomide Observational Effectiveness Study
-
CLINICAL_TRIALS study record update · 2021-07-28A Single-Dose, Randomized, Open-Label, 2-Way Crossover, Comparative Bioavailability Study of BLS-11 (Monomethyl Fumarate) 190 mg and Tecfidera (Dimethyl Fumarate) 240 mg in Healthy Male and Female Subjects Under Fasting Conditions
-
CLINICAL_TRIALS study record update · 2021-07-23A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
-
CLINICAL_TRIALS study record update · 2021-03-16Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)
-
CLINICAL_TRIALS study record update · 2020-11-25Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2020-11-09Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study
-
CLINICAL_TRIALS study record update · 2020-09-02A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2020-09-01Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)
-
CLINICAL_TRIALS study record update · 2020-07-14A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
-
CLINICAL_TRIALS study record update · 2020-02-25Safety, Tolerability And Mechanism Of Action Of Boswellic Acids In Multiple Sclerosis and Clinically Isolated Syndrome: A MRI-Controlled, Multicenter, Baseline-To-Treatment, 32-Weeks, Open-Label, Phase IIa Trial
-
CLINICAL_TRIALS study record update · 2019-10-31A Multicentric Randomized PRAGmatic Trial to Compare the Effectiveness of Fingolimod Versus Dimethyl-Fumarate on Patient Overall Disease Experience in Relapsing Remitting Multiple Sclerosis: Novel Data to Inform Decision-makers
-
CLINICAL_TRIALS study record update · 2019-10-04Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients
-
CLINICAL_TRIALS study record update · 2019-09-30Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients
-
CLINICAL_TRIALS study record update · 2019-04-01Patient Reported Outcomes With Fingolimod in Local Experience (PROFILE)
-
CLINICAL_TRIALS study record update · 2019-03-27An Active Extension of LAQ/5062 Study. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of Two Doses (0.3 mg and 0.6 mg) of Laquinimod, Orally Administered in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects (Study LAQ/5063 Active Double-Blind Phase) Followed by an Open Label Phase of Laquinimod 0.6 mg Daily (LAQ/5063 OL)
-
CLINICAL_TRIALS study record update · 2019-02-06Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2019-01-25A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.
-
CLINICAL_TRIALS study record update · 2018-11-07Assessment of the Clinical Importance of Insulin Resistance & Steroid-Associated Hyperglycemia in Relapsing Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2018-10-16Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients
-
CLINICAL_TRIALS study record update · 2018-10-09A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design
-
CLINICAL_TRIALS study record update · 2018-09-26Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2018-03-20Multicentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-β1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2018-03-20Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2018-02-15A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With Multiple Sclerosis
-
CLINICAL_TRIALS study record update · 2018-01-12A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)